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Background: Many patients with diabetes mellitus fail to achieve treatment targets   recommended 
in recognized guidelines. Little data is available in this area relating to young adults.
Objective: To assess whether treatment goals for glycosylated hemoglobin (HbA1c), blood 
pressure, lipid-lowering, and process outcomes for microvascular screening are being achieved 
in young adults with diabetes mellitus.
Methods: A retrospective clinical record audit of 202 consecutive patients with type 1 and type 
2 diabetes, aged predominantly 18–45 years, attending a specialist diabetes center in Brisbane, 
Australia, was conducted. Assessment was made as to whether goals for HbA1c, blood pressure, 
lipid lowering, and microvascular screening were being achieved. Descriptive statistics and 
comparison of continuous variables were produced.
Results: Mean (SD) HbA1c was 8.30% (±1.5) with no statistical difference between patients with 
type 1 and type 2 diabetes (P = 0.44). Sixteen percent of patients (12% type 1, 31% type 2) had an 
HbA1c of ,7%. Eighty-three percent of patients had blood pressure #130/80 mmHg. 
Sixteen   percent of patients with type 1 and 37% with type 2 diabetes were achieving combined 
lipid targets. Only 34% and 9% of patients who had an indication (and no documented contraindica-
tion) for lipid-lowering and antiplatelet therapy, respectively, were prescribed such agents. There 
was a significant difference in achievement of macrovascular treatment targets in patients with type 
1 and type 2 diabetes, but no difference in screening or treatment outcomes in microvascular disease. 
Patients below the age of 25 years were less likely to achieve macrovascular treatment targets.
Conclusion: A large number of young adult patients with diabetes mellitus do not achieve 
recognized treatment targets. There appears to be less emphasis placed on macrovascular risk 
factor targets compared with previous audits in older patients, in patients with type 1 diabetes 
compared with type 2 diabetes and in patients younger than 25 years.
Keywords: diabetes mellitus, complications, vascular risk, hypertension, cholesterol, glycated 
hemoglobin
Introduction
It is well established that intensive glycemic control with both type 1 and type 2 
  diabetes decreases microvascular diabetic complications.1–3 Aggressive treatment of 
other cardiovascular risk factors including hypertension4,5 and dyslipidemia6,7 is effec-
tive in decreasing cardiovascular risk. Although aspirin may be less effective in some 
diabetic patients in preventing cardiovascular events,8 it is still recommended.9
The outcomes of the Bogalusa Heart and The Pathobiological Determinants of 
  Atherosclerosis in Youth (PDAY) studies have established that overt cardiovascular 
disease in adults has its origins in youth, with the presence of multiple cardiovascular risk 
factors imparting greater risk.10,11 The only randomized studies in this age group involve Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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patients with familial   hypercholesterolemia,12 and it appears 
unlikely that other long-term studies will be conducted. 
Nonetheless, it has been suggested that aggressive risk factor 
modification in young people is justifiable and may in fact 
prevent, as opposed to merely decreasing the risk of, clini-
cally overt cardiovascular disease.13 Because type 114,15 and 
type 2 diabetes16 are independent risk factors for pre- and 
early atherosclerotic lesions in this age group, the justification 
for early and aggressive intervention is likely to be stronger 
in patients with diabetes mellitus.
Despite all that is known about the effectiveness of 
intervention in people with diabetes and many widely pub-
licized guidelines,9,17,18 multiple audits of diabetic care have 
demonstrated that a large proportion of patients are not 
achieving recommended treatment targets for HbA1c, lipid 
profile, and blood pressure control.19–24 Other than a large 
audit of German patients with type 1 diabetes,22 there is little 
data on the achievement of treatment targets and cardiovas-
cular risk factor modification in younger patients with 
diabetes.
Methods
This retrospective cohort audit study was performed to 
further elucidate the proportion of young adults with diabetes 
mellitus achieving treatment targets. The audit cohort sample 
included adults with diabetes mellitus attending a specialist 
diabetes clinic, specifically for young adult patients 
  (primarily aged between 18 and 45 years) at the Mater Hos-
pital,   Brisbane, Australia. This multidisciplinary clinic 
includes endocrinologists and training registrars, creden-
tialed diabetes educators, dieticians, and psychologists. The 
clinic is attended by patients with both type 1 and type 2 
diabetes. Data were collected for all patients who attended 
the clinic between September 2007 and March 2008. Patients 
were excluded if they had been followed up in the clinic 
for ,6 months (most patients were followed up every three 
months and therefore had at least two clinic reviews), in 
order to ensure that patients had received appropriate spe-
cialist intervention before inclusion in analysis. If patients 
had attended more than once during the period of the audit, 
data from the most recent attendance were used primarily. 
For data that are not necessarily required at each visit, for 
example, lipid profile or urine protein studies, the record 
was searched to ensure that it was checked within the appro-
priate screening period.
The primary outcome measures examined included the 
adequacy of glycemic control, cardiovascular risk factor 
control (blood pressure and lipid targets, smoking 
  cessation), as well as the appropriateness of microvascular 
  complication screening and treatment. Secondary aims 
were to identify any differences between patients with type 
1 and type 2 diabetes and patients younger or older than 
25 years.
The Mater Health Services Human Research Ethics 
  Committee (HREC) assessed this study to be a quality assur-
ance activity exempt from HREC review in accordance with 
National Health and Medical Research Council (NHMRC) 
guidelines. All patient data were nonidentifiable. There are 
no conflicts of interest.
Results were compared primarily against American Dia-
betes Association (ADA) treatment targets, screening and 
treatment recommendations for 2007, which were the most 
recent authoritative guidelines available at the time of the 
review (see Table 1).9
Data are presented as mean (standard deviation). Com-
parisons of continuous variables between groups were by 
one-way analysis of variance (ANOVA). Categorical variables 
were analyzed using χ  2 and Fisher’s exact tests as appropriate. 
Significance was accepted at the 5% level on two-tailed test-
ing for all analyses. Statistica V 8.0 (StatSoft, Tulsa, OK, 
USA) was used for all analyses.
Results
In total, 249 patients were available for analysis among 
whom 47 were excluded as they had been attending the clinic 
for ,6 months. Of the 202 included patients, 111 (55%) 
were female. The average age was 31.9 (±9.9) years. The 
majority of patients had type 1 diabetes mellitus (154, 76%). 
Forty-two patients (21%) had type 2 diabetes, with six 
diagnosed with other forms of diabetes (eg, genetic diabetes 
syndromes). We did not have access to data regarding patient 
ethnicity, though we noted that only 4/202 patients (2%, all 
type 2 diabetes) identified themselves as indigenous 
Australians.
Mean HbA1c was 8.30% (±1.5) with no statistical dif-
ference between patients with type 1 and type 2 diabetes 
(P = 0.44). Only 16% of patients (12% type 1, 31% type 
2) had an HbA1c of ,7%.
Eighty-seven percent of patients had their blood pressure 
checked at the visit used for this report. In total, 146 patients 
of 176 (83%) had blood pressure ,130/80 mmHg with 95% 
having blood pressure measurements #140/90 mmHg. Only 
75 (37%) had had their lipid profile checked and docu-
mented appropriately. Of those patients, 16% of patients Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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with type 1 and 37% with type 2 diabetes were achieving 
lipid targets, but in total, only 6.5% and 24%, respectively, 
of the total cohort had been clearly documented as reaching 
these targets. Of the patients who had an indication (and 
no documented contraindication) for lipid-lowering ther-
apy, 34% (23 of 67) were prescribed such agents. In 121 
patients (60%), it was unclear whether the patient was a 
current smoker. In the 22 patients who were identified as 
smokers, 9 were given smoking cessation advice. Only 6 
out of the 96 (9%) patients with an indication (and no 
contraindication) for antiplatelet therapy were actually 
prescribed this therapy.
Sixty-five percent of patients had been screened for 
microalbuminuria. Of the 20 patients with known neph-
ropathy, 15 had been prescribed an angiotensin-converting 
enzyme (ACE) inhibitor or angiotensin II receptor blocker 
(ARB) (two had contraindications). Thirty-four patients 
had retinopathy (22 nonproliferative, 8 proliferative, and 
4 severity not known). Seventy-three percent of those with-
out retinopathy had been appropriately screened within the 
past 2 years. Few patients had known peripheral neuropathy 
(9%). Ninety-four percent of patients had been screened 
for this in the past year, but only very few (9%) had been 
questioned regarding symptoms of autonomic neuropathy.
Tables 2 and 3 show the difference in demographics, 
glycemic control, and cardiovascular risk factor modifica-
tion between patients with type 1 and type 2 diabetes. 
Tables 4 and 5 outline the differences in treatment outcomes 
for patients with type 1 diabetes mellitus, comparing those 
younger or older than 25 years to those aged 25 years.
Discussion
Despite the overwhelming evidence that improving glycemic 
control and cardiovascular risk factor modification improves 
Table 1 Process and outcome parameters assessed based upon American Diabetes Association guidelines
Parameter Treatment target assessed
hbA1c ,7%
Blood pressure recorded at every visit  
,130/80 mmhg
Dyslipidemia In individuals without overt cardiovascular disease
 •   LDL #2.6 mmol/L
 •     For those aged over 40 years, statin therapy to achieve an LDL reduction of 30%–40% regardless of baseline LDL 
levels is recommended
 •     For those younger than 40 years, but at increased risk due to other cardiovascular risk factors who do not achieve 
lipid goals with lifestyle modifications alone, the addition of pharmacological therapy is appropriate 
In individuals with overt cVD
 •     Statin therapy where not otherwise contraindicated triglycerides 1.7 mmol/L and raise hDL cholesterol  
to .1.0 mmol/L in men and .1.3 mmol/L in women
Antiplatelet therapy Secondary prevention in diabetic individuals with history of cVD
Primary prevention strategy in those with type 1 or type 2 diabetes at increased cardiovascular risk, including 
those who are older than 40 years or who have additional risk factors (family history of cardiovascular disease, 
hypertension, smoking, dyslipidemia, or albuminuria)
nephropathy Annual screening for microalbuminuria  
Appropriate treatment with angiotensin-converting enzyme inhibitor or angiotensin 2 receptor blocker
retinopathy Screening at least every 2 years
neuropathy Annual screening for distal symmetric polyneuropathy  
Screening for autonomic neuropathy with symptoms and signs annually
Smoking Documentation about smoking habits  
Advice given about cessation (if appropriate)
Abbreviations: cVD, cardiovascular disease; hDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 2 Demographics and glycemic control in patients with 
type 1 and type 2 diabetes
Type 1 DM Type 2 DM P
number of patients 154 42
Weight (mean ± SD) (kg) 78.7 ± 17.9 93.6 ± 27.2 ,0.001
Age (mean ± SD)  
(years)
29.5 ± 16.1 39.6 ± 8.0 ,0.001
gender (% males) 48 31 ,0.001
hbA1c (mean ± SD) (%) 8.33 ± 1.35 8.13 ± 2.01 0.44
Achieving hbA1c ,7%  
(ratio and %)
19/154 (12) 13/42 (31) ,0.001
Abbreviations: DM, diabetes mellitus;  hbA1c, glycosylated hemoglobin; 
SD, standard deviation.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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outcomes for patients with type 1 and type 2 diabetes, most 
patients do not achieve recommended treatment targets. 
The results of our study are similar to recent audits of 
diabetes care outcomes in both a primary care setting23,24 
and specialist endocrinology clinics20 in   Australia. Our 
study adds to the literature by describing attainment of 
glycemic and cardiovascular risk factor modification tar-
gets in a young adult population. Most previous studies 
have involved much older patient groups than our study 
(mean age 58.3–64.4 years compared with 31.9 ± 
9.9 years).20,23–25 This audit attempts to address this deficit 
in knowledge.
glycemic control
The glycemic targets in the current study were achieved 
by a similar percentage of patients (12% type 1, 31% type 
2) to those in the previous audit of a specialist clinic (13% 
type 1, 30% type 2).20 More patients (46%–52%) were 
achieving an HbA1c ,7% in the primary care setting (type 
2 only).23,24 This is most likely explained by referral bias, 
with poor glycemic control being a frequent indication for 
specialist referral. However, these results and those of 
previous audits outline the inadequacy of our current treat-
ments and approaches to diabetic management at both a 
primary care and specialist level. Tight glycemic control 
in older patients with type 2 diabetes and established ath-
Table  3  comparison  of  treatment  and  outcome  measures   
in patients with type 1 and type 2 diabetes
Type 1 DM 
Number (%)
Type 2 DM 
Number (%)
P
Macrovascular risk factor modification targets
Process measures
  Blood pressure documented 131/154 (85) 40/42 (95) 0.372
  Lipid profile documented 44/154 (29) 27/42 (64) ,0.001
  Antiplatelet therapy indication 62/154 (40) 31/42 (74) ,0.001
    Appropriate prescription  
of antiplatelet therapy
3/62 (4.8) 6/34 (18) ,0.001
    Indication for lipid-lowering  
therapy
40/154 (26) 27/42 (64) ,0.001
    Appropriate prescription of  
lipid-lowering therapy
12/40 (30) 11/27 (41) ,0.001
Outcome measures
    Target blood  
pressure , 130/80
80/131 (61) 18/40 (45) 0.210
  Blood pressure # 140/90 124/131 (95) 39/40 (98) 0.505
  combined lipids target  
  (LDL , 2.6 mmol/L,  
  hDL . 1.0 mmol/L,  
  triglycerides , 1.7 mmol/L)
7/44 (16) 10/27 (28) 0.066
  LDL , 2.6 mmol/L 15/33 (45) 13/26 (50) 0.508
Microvascular complication and screening
Patients screened for  
nephropathy
86/139 (62) 24/37 (65) 0.889
Patients with nephropathy 15/154 (9.7) 5/42 (12) 0.831
Ace inhibitor/Ar2B prescribed 
for microalbuminuria/
nephropathy
11/15 (73) 4/5 (80) 0.422
Patients screened for  
retinopathy
96/127 (76) 25/35 (71) 0.104
Patients with known  
retinopathy
27/154 (18) 7/42 (17) 0.104
Patients with peripheral  
neuropathy
10/154 (6.5) 8/42 (19) 0.040
Screened for peripheral 
neuropathy
135/154 (88) 32/42 (76) 0.041
Abbreviations: Ace, angiotensin-converting enzyme; Ar2B, angiotensin 
2 receptor blocker; DM, diabetes mellitus; hDL, high-density lipoprotein; 
LDL, low-density lipoprotein.
Table 4 comparison of demographics and treatment outcomes 
in patients younger or older than 25 years
Age # 25 
years
Age . 25 
years
P
Age at time of visit (years)   21.6 ± 2.0   36.0 ± 7.8 ,0.001
Weight (kg)   77.6 ± 14.9   79.6 ± 20.0 0.015
hbA1c (%)   8.60 ± 1.56   8.13 ± 1.14 0.007
Blood pressure systolic (mmhg) 113.2 ± 15.2 118.4 ± 16.9 0.424
Blood pressure diastolic (mmhg)   67.7 ± 10.0   73.3 ± 10.0 0.987
LDL (mmol/L)   2.60 ± 0.88   2.80 ± 0.87 0.938
hDL (mmol/L)   1.70 ± 1.04   1.41 ± 0.33 ,0.001
Triglycerides (mmol/L)   1.79 ± 1.68   1.28 ± 0.69 ,0.001
Notes: Data are presented as mean standard ± deviation. P values measured by 
unpaired t-test.
Abbreviations: hbA1c, glycosylated hemoglobin; hDL, high-density lipoprotein; 
LDL, low-density lipoprotein.
Table 5 Comparison of macrovascular risk factor modification in 
patients younger or older than 25 years
Age # 25 years Age . 25 P
Number (%) Number (%)
Process measures
Indication for lipid-
lowering therapy
10/70 (14.3) 57/132 (43.1) ,0.001
Appropriate 
prescription of lipid-
lowering therapy
1/10 (10) 22/52 (42.3) ,0.001
Indication for 
antiplatelet therapy
18/69 (26.1) 78/132 (59.1) ,0.001
Appropriate 
prescription of 
antiplatelet therapy
0/18 (0) 9/71 (12.7) ,0.001
current smoker 6/26 (23.1) 16/55 (29.1) 0.620
Appropriate smoking 
cessation advice given
0/26 (0) 9/17 (52.9) 0.017
Outcome measures
combined blood 
pressure targets
43/70 (61.5) 58/132 (44.0) 0.026
combined lipid targets 3/67 (4.5) 17/132 (12.9) 0.080Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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erosclerosis appears to be associated with an increased rate 
of macrovascular events.26–28 However, in the younger 
cohorts of the United Kingdom Prospective Diabetes Study 
(UKPDS)29 and Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications 
(DCCT/EDIC)3 trials, tighter glycemic control conferred 
a benefit. Given this, aiming for tighter glycemic control 
in young patients and establishing the metabolic legacy 
early in the course of the disease, prior to the development 
of clinically overt cardiovascular disease, should be the 
focus.29,30
hypertension
Hypertension is more prevalent in patients with diabetes 
compared with the general population.31 In this audit, a 
much larger proportion of patients (83%) had recorded 
blood pressure measurements in the target range compared 
with most other studies (26%–28%).19,23 This is not surpris-
ing given that the populations of these studies were older 
and exclusively had type 2 diabetes, both of which will 
increase the prevalence of hypertension. Our audit cohort 
compares favorably with a report of similarly aged patients 
with type 1 diabetes from the United States,31 of whom only 
42% were achieving blood pressure targets. Our results are 
comparable to a large German audit of patients with type 
1 diabetes (ranging in age from 0.25–26 years),22 in which 
89%–97% of patients achieved blood pressure targets. 
However, of the 8.1% of patients with diagnosed hyperten-
sion in that study, only 0.4% were taking antihypertensive 
agents. Overall, these studies demonstrate that hypertension 
is less prevalent in younger age groups and is probably 
being treated more effectively than in older patients with 
type 2 diabetes. Nonetheless, almost 20% of young adults 
with diabetes in our audit still have inadequately treated 
hypertension.
Lipids
Younger patients with type 2 diabetes have less favorable 
lipid profiles than older patients.32 Despite this and its 
undoubted association with cardiovascular disease, dyslipi-
demia appears to be less than optimally treated in this young 
adult population with only a minority of patients having 
their lipid profiles fully documented within the past 2 years. 
A much smaller percentage (4.5% type 1, 24% type 2) were 
documented to be target or below for LDL, HDL, and trig-
lycerides. Of some reassurance, of those patients with a 
documented LDL, a much larger proportion (47%) had 
values less than the ADA target of 2.6 mmol/L. This apparent 
lack of attention to dyslipidemia management seems con-
cordant with the German cohort22 of Schwab et al in which 
only 2.1% of the 28.6% of patients with dyslipidemia were 
being treated. Interestingly, with the older populations of 
previous audits, dyslipidemia was more successfully 
identified and treated, with 22.5%–60% of patients achieving 
lipid targets.19,20
Smoking
There are a similar proportion of smokers in our audit com-
pared to ANDIAB (Australian National Diabetes Information 
Audit and Benchmarking) data (9.8% versus 9%).25 However, 
there appears to be less attention paid to smoking status in 
our population with 60% (compared with 12% in ANDIAB) 
of patients not having their smoking status documented. This 
disparity may relate to perceived overall cardiovascular risk, 
with older patients being at higher risk, at least in the short 
term, of adverse cardiovascular events and therefore most in 
need of risk factor modification.
Antiplatelet agents
Despite the limited data on efficacy of antiplatelet agents in 
primary prevention of cardiovascular events in diabetes 
mellitus8,33 (particularly in younger patients) and recent 
evidence in older patients with type 2 diabetes that aspirin 
may not provide a benefit,34 aspirin is still recommended for 
primary prevention in young patients with diabetes who 
have additional cardiovascular risk factors.9 The percentage 
of patients who were prescribed antiplatelet therapy in this 
audit is lower than in previous audits. Twenty-two percent 
of diabetic patients in the NHANES (National Health and 
Nutrition Examination Survey) 1999–2000 were regularly 
taking aspirin,21 compared with only 9% overall in this cur-
rent audit. This lack of convincing evidence may help 
explain why few patients have been prescribed antiplatelet 
therapy in this population. As for lipid-lowering and anti-
hypertensive therapy prescription, lack of patient insight 
and nonadherence may also mitigate against administration 
of antiplatelet agents.
Strengths and weaknesses
We believe that our report adds important information about 
control of diabetes and vascular risk factors in younger adults 
with diabetes. It represents a contemporary audit of processes 
and outcomes in a cohort of patients under specialist care 
and demonstrates how challenging providing optimal care Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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can be in this patient group. Our time-defined cohort from 
a single specialist center is unlikely to be representative of 
all young people with diabetes in Australia. In particular, 
the number of patients with type 2 diabetes in our sample 
is small. It is likely that these people are largely cared for 
in primary, nonspecialist practice. Our data do not allow 
firm conclusions to be drawn regarding causal factors 
related to intermediate outcomes such as risk factor control 
and are clearly inadequate to define the prevalence of actual 
cardiovascular events.
Possible causal factors
The reasons for our disappointing results are not clear, but 
many factors are likely to contribute. Anecdotally, young 
patients may refuse to start or be nonadherent to prescribed 
lipid-lowering or aspirin therapy. In a nondiabetic popula-
tion, reasons for nonadherence to statin therapy included 
young age, smoking, and the patients’ lack of perception 
that lipid-lowering therapy can help prevent cardiovascular 
events.35 Clinically, we note that young patients with diabetes 
often fail to comprehend the long-term consequences of 
poor glycemic control. We suspect that these patients will 
be similarly indifferent with regards to the effectiveness of 
lipid-lowering in preventing cardiovascular events. Some 
patients might be reluctant to start another medication that 
will continue lifelong, particularly if they do not fully appre-
ciate that it may provide some long-term benefit. Potentially, 
the cost of additional medications may be prohibitive in 
younger patients, particularly in students or those with only 
part-time jobs. Psychological factors such as depression and 
anxiety may also limit patient adherence to therapy.36 Clini-
cian factors are likely to play a role. Without evidence of 
efficacy from long-term prospective trials in young patients, 
clinicians may be disinclined to commence primary preven-
tative therapy management. Furthermore, physicians may 
feel that different treatment goals are more important in 
young patients, including ongoing rapport building and 
follow-up or glycemic control.
Although previous audits mentioned above have dem-
onstrated poor attainment of cardiovascular risk factor 
modification targets, our audit has established that even 
less importance is being placed on these factors in young 
adults with diabetes. Similarly, less attention appears to be 
paid to cardiovascular risk factors in young patients with 
type 1 diabetes compared with those who have type 2 
diabetes. There is little or no difference when comparing 
the screening and appropriate treatment of microvascular 
complications, but significant differences when comparing 
the process measures and outcomes of cardiovascular primary 
prevention. Patients with type 2 diabetes are more likely to 
have other features of the metabolic syndrome and may be 
perceived to be at greater long-term risk for cardiovascular 
events. Similar outcomes are seen in patients younger than 
25 compared with those older than 25 years, particularly with 
regard to primary cardiovascular risk factor modification. The 
perception that younger patients and those with type 1 diabetes 
are at lower risk may account for some of the disparity in 
macrovascular risk factor modification.
Further questions
There are many unanswered questions in this area that 
merit further research. Further assessment of treatment 
targets in a comparably young diabetic cohort could assess 
whether the trend of apparent lack of attention to macro-
vascular risk factor modification found in our audit is 
replicated in other centers. The potential reasons outlined 
above to explain our results are largely anecdotal and 
deserve further evaluation. It remains uncertain how much 
they are contributing, if at all, to the outcomes of our audit. 
Furthermore, it is not clear whether the factors leading to 
poor attainment of treatment targets in previous audits with 
older populations are of equal importance in our population. 
It is uncertain how these targets may be improved in an 
older adult population, but some recent data from Varma 
et al37 have demonstrated better attainment of treatment 
targets with community-based endocrinology practice in 
the United States. However, this program involves an inten-
sive follow-up regimen and it is not clear whether the 
resources are available in   Australia to replicate these results 
and whether the same improvement will be seen in younger 
adults with diabetes mellitus. Our results do identify a clear 
evidence practice gap and set the agenda for further detailed 
epidemiologic and intervention trials.
Conclusion
A large number of young adult patients with diabetes mellitus 
do not achieve recognized treatment targets. There appears 
to be less emphasis placed on macrovascular risk factor 
targets compared with previous audits in older patients, in 
patients with type 1 diabetes compared with type 2 diabetes 
and in patients younger than 25 years. The reasons for these 
discrepancies  remain  unclear,  but  warrant  further 
investigation.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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